【24h】

Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?

机译:临床前抗癌药的临床开发-最佳的临床前模型是什么?

获取原文
获取原文并翻译 | 示例
           

摘要

The successful identification of novel effective anticancer drugs is largely dependent on the use of appropriate preclinical experimental models that should possibly mimic the complexity of different cancer diseases. The huge number of targets suitable for the design of new anticancer drugs is producing hundreds of novel molecules that require appropriate experimental models to investigate their mode of action and antitumour activity in order to select for clinical investigation the ones with higher chances of being clinically effective. However, our ability to predict the clinical efficacy of a new compound in the clinic based on preclinical data is still limited. This paper overviews the in vitro/in vivo preclinical systems that are currently used to test either compounds with an unknown mechanism of action or compounds designed to hit cancer-specific or cancer-related molecular targets. Examples of experimental models successfully used to identify novel compounds are provided. Xenografts are still the most commonly used in vivo models in drug development due to their high degree of reproducibility and because, in some cases, particularly when orthotopically transplanted, they maintain several biological properties of the human tumours they derive from. Genetic models are very useful for target validation, but are often not sufficiently reproducible to be used for drug evaluation. The variety of animal models can be effectively used to optimally test drugs that presumably act by a defined mode of action, but final success is highly dependent on the ability of drug development teams to integrate different expertises such as biology, chemistry, pharmacology, toxicology and clinical oncology into a clever and well orchestrated plan that keeps in consideration both the complexity of cancer diseases, involving alterations of different pathways, and the complexity of drugs whose pharmacological properties are crucial to obtain the desired effects.
机译:新型有效抗癌药物的成功鉴定很大程度上取决于适当的临床前实验模型的使用,该模型可能会模拟不同癌症疾病的复杂性。适合设计新的抗癌药物的大量靶标产生了数百种新颖的分子,这些分子需要适当的实验模型来研究其作用方式和抗肿瘤活性,以便为临床研究选择具有更高临床疗效的可能性。但是,我们根据临床前数据预测新化合物在临床上的临床疗效的能力仍然有限。本文概述了目前用于测试具有未知作用机理的化合物或旨在击中癌症特异性或癌症相关分子靶标的化合物的体外/体内临床前系统。提供了成功用于鉴定新型化合物的实验模型的实例。由于异种移植物的高度可再现性,并且因为在某些情况下,尤其是在原位移植时,它们保持了其衍生的人类肿瘤的几种生物学特性,因此它们仍然是药物开发中最常用的体内模型。遗传模型对于靶标验证非常有用,但通常不能充分重现以用于药物评估。各种动物模型都可以有效地用于优化测试可能以定义的作用方式起作用的药物,但是最终的成功很大程度上取决于药物研发团队整合不同专业知识(如生物学,化学,药理学,毒理学和将临床肿瘤学纳入一个巧妙且精心安排的计划中,该计划既要考虑到癌症疾病的复杂性(涉及不同途径的改变),又要考虑其药理学性质对于获得理想效果至关重要的药物的复杂性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号